Moolec Science S.A. (MLEC) Financial Ratios
5 years of historical data (2020–2024) · Healthcare · Biotechnology
EV/EBITDA
↓
21.45
↓-46% vs avg
5yr avg: 39.40
30Y Low21.1·High57.7
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 7.05
30Y Low0.1·High15.6
ROE
↓
N/A
—
5yr avg: -244.4%
30Y Low-86%·High-0%
Debt/EBITDA
↑
20.97
↑+94% vs avg
5yr avg: 10.81
30Y Low0.6·High21.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MLEC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Moolec Science S.A. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $7M | $3M | $28M | $85M | $25M | $11M |
| Enterprise Value | $253M | $249M | $38M | $85M | $24M | $11M |
| P/E Ratio → | -0.03 | — | — | — | — | — |
| P/S Ratio | 0.02 | 0.01 | 5.02 | 93.43 | — | — |
| P/B Ratio | — | — | 4.14 | 8.37 | 15.59 | 0.08 |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MLEC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Moolec Science S.A.'s enterprise value stands at 21.5x EBITDA, 46% below its 5-year average of 39.4x. The Healthcare sector median is 14.5x, placing the stock at a 48% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.75 | 6.67 | 93.56 | — | — |
| EV / EBITDA | 21.45 | 21.13 | — | — | — | 57.67 |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
MLEC Profitability
Margins and return-on-capital ratios measuring operating efficiency
Moolec Science S.A. earns an operating margin of -3.1%. Operating margins have expanded from -735.2% to -3.1% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 34.2% | 34.2% | 8.4% | -15.8% | — | — |
| Operating Margin | -3.1% | -3.1% | -160.8% | -735.2% | — | — |
| Net Profit Margin | -33.4% | -33.4% | -130.0% | -5722.2% | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | — | — | -86.4% | -884.5% | -6.7% | -0.0% |
| ROA | -93.1% | -93.1% | -24.9% | -348.2% | -6.3% | -0.0% |
| ROIC | -8.8% | -8.8% | -51.5% | -91.8% | -1.9% | — |
| ROCE | — | — | -47.5% | -101.9% | -2.5% | -0.0% |
MLEC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Moolec Science S.A. carries a Debt/EBITDA ratio of 21.0x, which is highly leveraged (535% above the sector average of 3.3x). Net debt stands at $246M ($247M total debt minus $767919 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 2.15 | 0.26 | 0.08 | 0.00 |
| Debt / EBITDA | 20.97 | 20.97 | — | — | — | 0.65 |
| Net Debt / Equity | — | — | 1.36 | 0.01 | -0.60 | -0.00 |
| Net Debt / EBITDA | 20.90 | 20.90 | — | — | — | -1.10 |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -0.25 | -0.25 | -7.76 | -41.58 | -805.94 | — |
MLEC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.13x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.42x to 0.13x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.13 | 0.13 | 1.69 | 0.42 | 0.27 | 0.67 |
| Quick Ratio | 0.12 | 0.12 | 0.92 | 0.39 | 0.27 | 0.67 |
| Cash Ratio | 0.04 | 0.04 | 0.66 | 0.22 | 0.26 | 0.39 |
| Asset Turnover | — | 1.63 | 0.16 | 0.04 | — | — |
| Inventory Turnover | 98.23 | 98.23 | 0.82 | 2.25 | — | — |
| Days Sales Outstanding | — | 21.80 | 96.17 | 682.08 | — | — |
MLEC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Moolec Science S.A. returns 14.2% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 14.2% | 34.1% | 1.1% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 14.2% | 34.1% | 1.1% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $430864 | $3M | $2M | $3M | $1M |
Peer Comparison
Compare MLEC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MLECYou | $7M | -0.0 | 21.5 | — | 34.2% | -3.1% | — | -8.8% | 21.0 |
 RKDA | $2M | -0.6 | — | — | 36.2% | -205.7% | -45.1% | -249.2% | — |
 PGEN | $1B | -8.8 | — | — | -8.7% | -3440.2% | -160.8% | -152.8% | — |
 SLP | $324M | -5.0 | — | 18.6 | 58.4% | -89.3% | -42.1% | -39.6% | — |
 BYND | $414M | -0.5 | — | — | 2.8% | -84.7% | — | -44.4% | — |
 SMPL | $1B | 12.2 | 6.0 | 7.9 | 35.1% | 15.1% | 5.9% | 8.1% | 1.3 |
 ADM | $37B | 34.8 | 17.2 | 8.9 | 6.3% | 1.8% | 4.7% | 3.3% | 3.2 |
 BG | $24B | 25.2 | 22.6 | — | 4.5% | 1.5% | 5.8% | 3.3% | 9.6 |
 CTVA | $53B | 49.4 | 13.4 | 18.9 | 43.6% | 15.1% | 4.5% | 8.5% | 0.7 |
 FMC | $2B | -0.8 | — | — | 37.0% | -54.4% | -67.8% | -21.2% | — |
 CF | $18B | 13.2 | 6.2 | 10.1 | 38.5% | 33.4% | 18.9% | 18.7% | 1.2 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See MLEC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MLEC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MLEC vs RKDA
Side-by-side business, growth, and profitability comparison vs Arcadia Biosciences, Inc..
Start ComparisonMLEC — Frequently Asked Questions
Quick answers to the most common questions about buying MLEC stock.
What is Moolec Science S.A.'s P/E ratio?
Moolec Science S.A.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
What is Moolec Science S.A.'s EV/EBITDA?
Moolec Science S.A.'s current EV/EBITDA is 21.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 39.4x.
Is MLEC stock overvalued?
Based on historical data, Moolec Science S.A. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Moolec Science S.A.'s profit margins?
Moolec Science S.A. has 34.2% gross margin and -3.1% operating margin.
How much debt does Moolec Science S.A. have?
Moolec Science S.A.'s Debt/EBITDA ratio is 21.0x, indicating high leverage. A ratio above 4x may signal elevated financial risk.